Gain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesis

Human Molecular Genetics

Volumn 19, Issue 7, 2010, Pages 1199-1210

  Su, Nan ^a   Sun, Qidi ^a   Li, Can ^a   Lu, Xiumin ^a   Qi, Huabing ^a   Chen, Siyu ^a   Yang, Jing ^a,b   Du, Xiaolan ^a,b   Zhao, Ling ^a   He, Qifen ^a   Jin, Min ^a   Shen, Yue ^a   Chen, Di ^b   Chen, Lin ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SYNAPTOPHYSIN;

ACHONDROPLASIA; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MARROW CELL; BONE MASS; BONE MATRIX; BONE MINERALIZATION; CELL COUNT; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENE MUTATION; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STROMA CELL; TRABECULAR BONE; UPREGULATION; WILD TYPE;

ACHONDROPLASIA; ANIMALS; BONE DENSITY; BONE RESORPTION; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; CELL PROLIFERATION; CHONDROGENESIS; DISEASE MODELS, ANIMAL; MICE; MUTATION; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; UP-REGULATION;

MUS;

EID: 77952523094     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddp590     Document Type: Article

References (61)

1. Ornitz, D.M. and Marie, P.J. (2002) FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev., 16, 1446-1465.
2. Su, N., Du, X. and Chen, L. (2008) FGF signaling: its role in bone development and human skeleton diseases. Front. Biosci., 13, 2842-2865.
3. Naski, M.C. and Ornitz, D.M. (1998) FGF signaling in skeletal development. Front. Biosci., 3, d781-d794.
4. Ornitz, D.M. (2005) FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev., 16, 205-213.
5. Toydemir, R.M., Brassington, A.E., Bayrak-Toydemir, P., Krakowiak, P.A., Jorde, L.B., Whitby, F.G., Longo, N., Viskochil, D.H., Carey, J.C. and Bamshad, M.J. (2006) A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome. Am. J. Hum. Genet., 79, 935-941.
6. Richette, P., Bardin, T. and Stheneur, C. (2008) Achondroplasia: from genotype to phenotype. Joint Bone Spine, 75, 125-130.
7. Rousseau, F., el Ghouzzi, V., Delezoide, A.L., Legeai-Mallet, L., Le Merrer, M., Munnich, A. and Bonaventure, J. (1996) Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). Hum. Mol. Genet., 5, 509-512.
8. Horton, W.A. and Lunstrum, G.P. (2002) Fibroblast growth factor receptor 3 mutations in achondroplasia and related forms of dwarfism. Rev. Endocr. Metab. Disord., 3, 381-385.
9. Rousseau, F., Bonaventure, J., Legeai-Mallet, L., Pelet, A., Rozet, J.M., Maroteaux, P., Le Merrer, M. and Munnich, A. (1994) Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature, 371, 252-254.
10. Naski, M.C., Colvin, J.S., Coffin, J.D. and Ornitz, D.M. (1998) Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development, 125, 4977-4988.
11. Chen, L., Adar, R., Yang, X., Monsonego, E.O., Li, C., Hauschka, P.V., Yayon, A. and Deng, C.X. (1999) Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis. J. Clin. Invest., 104, 1517-1525.
12. Datta, H.K., Ng, W.F., Walker, J.A., Tuck, S.P. and Varanasi, S.S. (2008) The cell biology of bone metabolism. J. Clin. Pathol., 61, 577-587.
13. Bilezikian, J.P., Matsumoto, T., Bellido, T., Khosla, S., Martin, J., Recker, R.R., Heaney, R., Seeman, E., Papapoulos, S. and Goldring, S.R. (2009) Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J. Bone Miner. Res., 24, 373-385.
14. Meyers, G.A., Orlow, S.J., Munro, I.R., Przylepa, K.A. and Jabs, E.W. (1995) Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat. Genet., 11, 462-464.
15. Arnaud-Lopez, L., Fragoso, R., Mantilla-Capacho, J. and Barros-Nunez, P. (2007) Crouzon with acanthosis nigricans. Further delineation of the syndrome. Clin. Genet., 72, 405-410.
16. Wilkes, D., Rutland, P., Pulleyn, L.J., Reardon, W., Moss, C., Ellis, J.P., Winter, R.M. and Malcolm, S. (1996) A recurrent mutation, ala391glu, in the transmembrane region of FGFR3 causes Crouzon syndrome and acanthosis nigricans. J. Med. Genet., 33, 744-748.
17. Muenke, M., Gripp, K.W., McDonald-McGinn, D.M., Gaudenz, K., Whitaker, L.A., Bartlett, S.P., Markowitz, R.I., Robin, N.H., Nwokoro, N., Mulvihill, J.J. et al. (1997) A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. Am. J. Hum. Genet., 60, 555-564.
18. Tavormina, P.L., Shiang, R., Thompson, L.M., Zhu, Y.Z., Wilkin, D.J., Lachman, R.S., Wilcox, W.R., Rimoin, D.L., Cohn, D.H. and Wasmuth, J.J. (1995) Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat. Genet., 9, 321-328.
19. Karadimas, C., Trouvas, D., Haritatos, G., Makatsoris, C., Dedoulis, E., Velissariou, V., Antoniadi, T., Hatzaki, A. and Petersen, M.B. (2006) Prenatal diagnosis of achondroplasia presenting with multiple-suture synostosis: a novel association. Prenat. Diagn., 26, 258-261.
20. Valverde-Franco, G., Liu, H., Davidson, D., Chai, S., Valderrama-Carvajal, H., Goltzman, D., Ornitz, D.M. and Henderson, J.E. (2004) Defective bone mineralization and osteopenia in young adult FGFR3-/-mice. Hum. Mol. Genet., 13, 271-284.
21. Eswarakumar, V.P. and Schlessinger, J. (2007) Skeletal overgrowth is mediated by deficiency in a specific isoform of fibroblast growth factor receptor 3. Proc. Natl. Acad. Sci. USA, 104, 3937-3942.
22. Franceschi, R.T. and Xiao, G. (2003) Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J. Cell. Biochem., 88, 446-454.
23. Ge, C., Xiao, G., Jiang, D. and Franceschi, R.T. (2007) Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. J. Cell. Biol., 176, 709-718.
24. Jacob, A.L., Smith, C., Partanen, J. and Ornitz, D.M. (2006) Fibroblast growth factor receptor 1 signaling in the osteo-chondrogenic cell lineage regulates sequential steps of osteoblast maturation. Dev. Biol., 296, 315-328.
25. Yu, K., Xu, J., Liu, Z., Sosic, D., Shao, J., Olson, E.N., Towler, D.A. and Ornitz, D.M. (2003) Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development, 130, 3063-3074.
26. Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R.T., Gao, Y.H., Inada, M. et al. (1997) Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell, 89, 755-764.
27. Ducy, P., Starbuck, M., Priemel, M., Shen, J., Pinero, G., Geoffroy, V., Amling, M. and Karsenty, G. (1999) A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev., 13, 1025-1036.
28. Xiao, G., Jiang, D., Thomas, P., Benson, M.D., Guan, K., Karsenty, G. and Franceschi, R.T. (2000) MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J. Biol. Chem., 275, 4453-4459.
29. Funato, N., Ohtani, K., Ohyama, K., Kuroda, T. and Nakamura, M. (2001) Common regulation of growth arrest and differentiation of osteoblasts by helix-loop-helix factors. Mol. Cell. Biol., 21, 7416-7428.
30. Zhou, Y.X., Xu, X., Chen, L., Li, C., Brodie, S.G. and Deng, C.X. (2000) A Pro250Arg substitution in mouse Fgfr1 causes increased expression of Cbfa1 and premature fusion of calvarial sutures. Hum. Mol. Genet., 9, 2001-2008.
31. Marie, P.J. (2003) Fibroblast growth factor signaling controlling osteoblast differentiation. Gene, 316, 23-32.
32. Xiao, G., Jiang, D., Gopalakrishnan, R. and Franceschi, R.T. (2002) Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1/Runx2. J. Biol. Chem., 277, 36181-36187.
33. Huang, Z., Cheng, S.L. and Slatopolsky, E. (2001) Sustained activation of the extracellular signal-regulated kinase pathway is required for extracellular calcium stimulation of human osteoblast proliferation. J. Biol. Chem., 276, 21351-21358.
34. Lee, S.W., Choi, K.Y., Cho, J.Y., Jung, S.H., Song, K.B., Park, E.K., Choi, J.Y., Shin, H.I., Kim, S.Y., Woo, K.M. et al. (2006) TGF-beta2 stimulates cranial suture closure through activation of the Erk-MAPK pathway. J. Cell. Biochem., 98, 981-991.
35. Lai, C.F., Chaudhary, L., Fausto, A., Halstead, L.R., Ory, D.S., Avioli, L.V. and Cheng, S.L. (2001) Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells. J. Biol. Chem., 276, 14443-14450.
36. Kono, S.J., Oshima, Y., Hoshi, K., Bonewald, L.F., Oda, H., Nakamura, K., Kawaguchi, H. and Tanaka, S. (2007) Erk pathways negatively regulate matrix mineralization. Bone, 40, 68-74.
37. Higuchi, C., Myoui, A., Hashimoto, N., Kuriyama, K., Yoshioka, K., Yoshikawa, H. and Itoh, K. (2002) Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. J. Bone Miner. Res., 17, 1785-1794.
38. Rodriguez, J.P., Rios, S., Fernandez, M. and Santibanez, J.F. (2004) Differential activation of ERK1,2 MAP kinase signaling pathway in mesenchymal stem cell from control and osteoporotic postmenopausal women. J. Cell Biochem., 92, 745-754.
39. Kim, H.J., Lee, M.H., Park, H.S., Park, M.H., Lee, S.W., Kim, S.Y., Choi, J.Y., Shin, H.I., Kim, H.J. and Ryoo, H.M. (2003) Erk pathway and activator protein 1 play crucial roles in FGF2-stimulated premature cranial suture closure. Dev. Dyn., 227, 335-346.
40. Xiao, G., Gopalakrishnan, R., Jiang, D., Reith, E., Benson, M.D. and Franceschi, R.T. (2002) Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells. J. Bone Miner. Res., 17, 101-110.
41. Raucci, A., Laplantine, E., Mansukhani, A. and Basilico, C. (2004) Activation of the ERK1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes. J. Biol. Chem., 279, 1747-1756.
42. Suzuki, A., Guicheux, J., Palmer, G., Miura, Y., Oiso, Y., Bonjour, J.P. and Caverzasio, J. (2002) Evidence for a role of p38 MAP kinase in expression of alkaline phosphatase during osteoblastic cell differentiation. Bone, 30, 91-98.
43. Hu, Y., Chan, E., Wang, S.X. and Li, B. (2003) Activation of p38 mitogen-activated protein kinase is required for osteoblast differentiation. Endocrinology, 144, 2068-2074.
44. Lee, K.S., Hong, S.H. and Bae, S.C. (2002) Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein. Oncogene, 21, 7156-7163.
45. Martin, T., Gooi, J.H. and Sims, N.A. (2009) Molecular mechanisms in coupling of bone formation to resorption. Crit. Rev. Eukaryot. Gene Expr., 19, 73-88.
46. Boyle, W.J., Simonet, W.S. and Lacey, D.L. (2003) Osteoclast differentiation and activation. Nature, 423, 337-342.
47. Zhao, Q., Shao, J., Chen, W. and Li, Y.P. (2007) Osteoclast differentiation and gene regulation. Front. Biosci., 12, 2519-2529.
48. Khosla, S. (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology, 142, 5050-5055.
49. Kawaguchi, H., Chikazu, D., Nakamura, K., Kumegawa, M. and Hakeda, Y. (2000) Direct and indirect actions of fibroblast growth factor 2 on osteoclastic bone resorption in cultures. J. Bone Miner. Res., 15, 466-473.
50. Amizuka, N.C., Chen, M.F., Goodyer, C., Sasaki, T. and Asawa, Y. (2001) Abnormalities in development of the growth plates of thanatophoric dysplasia type II fetuses result from enhanced vascular invasion and osteoclastic activity. J. Bone Miner. Res., 16, S1.
51. Chikazu, D., Hakeda, Y., Ogata, N., Nemoto, K., Itabashi, A., Takato, T., Kumegawa, M., Nakamura, K. and Kawaguchi, H. (2000) Fibroblast growth factor (FGF)-2 directly stimulates mature osteoclast function through activation of FGF receptor 1 and p42/p44 MAP kinase. J. Biol. Chem., 275, 31444-31450.
52. Shimoaka, T., Ogasawara, T., Yonamine, A., Chikazu, D., Kawano, H., Nakamura, K., Itoh, N. and Kawaguchi, H. (2002) Regulation of osteoblast, chondrocyte, and osteoclast functions by fibroblast growth factor (FGF)-18 in comparison with FGF-2 and FGF-10. J. Biol. Chem., 277, 7493-7500.
53. Montero, A., Okada, Y., Tomita, M., Ito, M., Tsurukami, H., Nakamura, T., Doetschman, T., Coffin, J.D. and Hurley, M.M. (2000) Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J. Clin. Invest., 105, 1085-1093.
54. Hurley, M.M., Okada, Y., Xiao, L., Tanaka, Y., Ito, M., Okimoto, N., Nakamura, T., Rosen, C.J., Doetschman, T. and Coffin, J.D. (2006) Impaired bone anabolic response to parathyroid hormone in Fgf2-/-and Fgf2+/-2 mice. Biochem. Biophys. Res. Commun., 341, 989-994.
55. Su, N., Yang, J., Xie, Y., Du, X., Lu, X., Yin, Z., Yin, L., Qi, H., Zhao, L., Feng, J. et al. (2008) Gain-of-function mutation of FGFR3 results in impaired fracture healing due to inhibition of chondrocyte differentiation. Biochem. Biophys. Res. Commun., 376, 454-459.
56. Osyczka, A.M. and Leboy, P.S. (2005) Bone morphogenetic protein regulation of early osteoblast genes in human marrow stromal cells is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase signaling. Endocrinology, 146, 3428-3437.
57. Yin, L., Du, X., Li, C., Xu, X., Chen, Z., Su, N., Zhao, L., Qi, H., Li, F., Xue, J. et al. (2008) A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis. Bone, 42, 631-643.
58. Kawaguchi, J., Mee, P.J. and Smith, A.G. (2005) Osteogenic and chondrogenic differentiation of embryonic stem cells in response to specific growth factors. Bone, 36, 758-769.
59. Liu, Z., Shi, W., Ji, X., Sun, C., Jee, W.S., Wu, Y., Mao, Z., Nagy, T.R., Li, Q. and Cao, X. (2004) Molecules mimicking Smad1 interacting with Hox stimulate bone formation. J. Biol. Chem., 279, 11313-11319.
60. Song, C., Guo, Z., Ma, Q., Chen, Z., Liu, Z., Jia, H. and Dang, G. (2003) Simvastatin induces osteoblastic differentiation and inhibits adipocytic differentiation in mouse bone marrow stromal cells. Biochem. Biophys. Res. Commun., 308, 458-462.
61. Kato, Y., Boskey, A., Spevak, L., Dallas, M., Hori, M. and Bonewald, L.F. (2001) Establishment of an osteoid preosteocyte-like cell MLO-A5 that spontaneously mineralizes in culture. J. Bone Miner. Res., 16, 1622-1633.